Gus Johnson

Cerebri AI solves problems – we solve your problems by using state-of-the-art data engineering and AI modeling to provide you with insights that will help you crush your competitors. Better decisions start with better data that drive deeper insights into your business. We use our ATQ data engineering platform to provide our reporting and modeling engines with the highest quality data possible. What data quality level do we have to get to? Certainly, a higher quality level than what everyone else uses – especially your competitors! And we do it in near real-time. What is the use of having better data to work with in making decisions if it arrives after it is needed? Our data engineering platform does not simply pass the data along; we have dozens of data transformers that can be deployed to QA and reconcile data from as many datasets as are required to get the job done. The goal of our data engineering is to get to one source of truth that includes the engineered features selected by our data scientists that drive the best possible results. Our one source of truth drives all of our reporting, business intelligence modeling, and our AI modeling. No more second guessing if the data matches up one report to another, including AI-based metrics. High-quality data drives the very best results when coupled with a wealth of data science experience. Our team has done over 100 installations in the largest corporate users in the world over the past two decades. We love solving the most complex analytical problems. We love corporate travel because most of the corporate travel datasets in this $1 trillion spend category reside outside of the enterprise, thus requiring serious levels of data engineering to make them useful. We love sustainability problems, including the challenges of calculating CO2 emissions. If you think we can help, please contact us; we would love to hear from you.

Astrocyte Pharmaceuticals is a clinical-stage drug discovery and development company dedicated to accelerating the recovery and well-being of brain injury patients. Astrocyte is committed to proving the neuro- and cerebroprotective benefits of enhanced mitochondrial energy production in astrocytes, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.

At GXC, we’re transforming the way businesses connect with our turnkey private 5G and LTE solutions. We make it easy for enterprises to take full control of their networks with seamless integration and simple management. Why GXC? Ready-to-Deploy Solution: Our turnkey system is quick to set up and manage, saving time and resources. Cost-Effective Integration: Our solution fits right into your existing infrastructure without breaking the bank. Streamlined Management: Our Enterprise Management System gives you real-time control over your entire network. Future-Ready, Flexible, and Secure Advanced Mesh Technology: Extend coverage easily without relying on traditional wired backhaul. Durable and Versatile Equipment: Built to perform in any environment—indoors or out. Dual-Band Capability: Future-proof your investment with technology that’s ready for 4G LTE and 5G. Strong Security and Seamless Integration Top-Tier Security: Our networks are secured with cellular-grade encryption to protect your data. API Support: Easily integrate with your current systems for smooth, proactive network management. We’re simplifying enterprise connectivity with private 5G. Learn more at www.gxc.io.

M87 Powers the Proximate Internet. M87 is the global leader in providing software solutions that enable billions of mobile devices to self-discover and form dynamic, self-communicating device-to-device networks. Our software improves the performance of today's mobile networks and enables connectivity in challenging IoT environments.  Today, M87 has two core applications of our groundbreaking device-to-device software.   - A full stack software solution that enables the $1T wireless industry to economically improve coverage, throughput, and capacity by leveraging smartphones for routing and bridging data paths to the network. - An SDK with exposed APIs that can be used by app developers and IoT companies to tap the power of proximate device discovery, authentication, communication, and location to enable new capabilities for their applications – Communication as a Platform.

(Accordion Health, Inc. is acquired by Evolent Health, Inc. in June 2017) Accordion Health is a healthcare predictive analytics company that provides targeted guidance using machine learning technologies. Our products are currently used by several Medicare Advantage plans and healthcare service organizations to increase their value-based reimbursement payments and improve their work efficiencies. Our mission is to transform our healthcare sustainable using cutting-edge data analytics techniques. For more information, please find us at https://accordionhealth.com. - For our deep learning APIs: https://developers.accordionhealth.com/ - Please contact yubin [at] accordionhealth [dot] com for more information.

MolecularMatch, Inc. is a Houston, Texas-based clinical informatics SaaS company founded in 2014 out of MD Anderson Cancer Center. The company was founded on the vision of using tumor molecular profiling, and outcomes from previously-treated patients, to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include genetic labs, health information systems, biopharma, hospitals, and cancer centers.

DECISIO Health is a Houston-based digital health company with a critical condition surveillance and decision support platform that aggregates data from the EHR, in-room medical devices, and other sources of clinical data - presenting that information on visually configurable dashboards. The flagship product, InsightIQ, uses continuous smart bedside surveillance which assist clinical teams to efficiently identify patients at risk and comply with established clinical guidelines - thus decreasing hospital complications, reducing LOS, and eliminating CMS penalties. Our solutions can be scaled across an entire health system or used in a single care area.

Headquartered in Austin, Texas, Lung Therapeutics, Inc. is a clinical stage biopharmaceutical company formed to leverage decades of leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing a proprietary pipeline of therapeutics with the potential to greatly improve outcomes over currently available treatments. The company’s lead drug candidate, LTI-01, is in clinical development for Loculated Pleural Effusion (LPE) and has successfully completed a clinical trial in LPE patients. The company’s second drug candidate, LTI-03, is in clinical development for Idiopathic Pulmonary Fibrosis (IPF).

Mobia Medical, Inc. (formerly MicroTransponder, Inc.) is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Companys breakthrough Vivistim® Paired VNS™ System is the first FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Vivistim Paired VNS Therapy combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive meaningful improvements in motor function. For more information, visit Vivistim.com and review safety information at Vivistim.com/safety.

Ascension Ventures (AV) helps accelerate innovation through strategic investment in early to late-stage companies across three healthcare sectors: services, technology, and medtech/devices. With five funds and over $1B under management, AV invests on behalf of 450+ leading hospitals nationwide. AV’s 13 health system limited partners (LPs) represent over 580,000 employees and generate $96B in annual revenue. Launched in 2001 by Ascension, AV pioneered an ecosystem investment model that brings a strategic lens to purposeful investing. This unique perspective empowers AV to partner in a differentiated way: identifying and investing in solutions that transform healthcare. We bring an in-depth understanding of our partner organizations and seek to make connections among our team with a singular goal: smart investments that improve healthcare. We’ve invested in nearly 80 companies and facilitated thousands of conversations between idea generators and health system executives. AV is passionate about finding real solutions to problems in healthcare. To learn more, please visit www.ascensionventures.org.

Cerebri AI solves problems – we solve your problems by using state-of-the-art data engineering and AI modeling to provide you with insights that will help you crush your competitors. Better decisions start with better data that drive deeper insights into your business. We use our ATQ data engineering platform to provide our reporting and modeling engines with the highest quality data possible. What data quality level do we have to get to? Certainly, a higher quality level than what everyone else uses – especially your competitors! And we do it in near real-time. What is the use of having better data to work with in making decisions if it arrives after it is needed? Our data engineering platform does not simply pass the data along; we have dozens of data transformers that can be deployed to QA and reconcile data from as many datasets as are required to get the job done. The goal of our data engineering is to get to one source of truth that includes the engineered features selected by our data scientists that drive the best possible results. Our one source of truth drives all of our reporting, business intelligence modeling, and our AI modeling. No more second guessing if the data matches up one report to another, including AI-based metrics. High-quality data drives the very best results when coupled with a wealth of data science experience. Our team has done over 100 installations in the largest corporate users in the world over the past two decades. We love solving the most complex analytical problems. We love corporate travel because most of the corporate travel datasets in this $1 trillion spend category reside outside of the enterprise, thus requiring serious levels of data engineering to make them useful. We love sustainability problems, including the challenges of calculating CO2 emissions. If you think we can help, please contact us; we would love to hear from you.

Astrocyte Pharmaceuticals is a clinical-stage drug discovery and development company dedicated to accelerating the recovery and well-being of brain injury patients. Astrocyte is committed to proving the neuro- and cerebroprotective benefits of enhanced mitochondrial energy production in astrocytes, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.